Summary
According to recent prospective studies, hypofibrinolysis due to elevated plasma plasminogen activator inhibitor 1 levels appears to be an independent risk factor for myocardial reinfarction in men, and hyperinsulinaemia, a major indicator of insulin resistance is considered as a risk factor for coronary disease. It has recently been shown that insulin resistance is accompanied by an increased plasma plasminogen activator inhibitor 1 concentration: A significant correlation coefficient was demonstrated between plasminogen activator inhibitor 1 and fasting plasma insulin in the normal population, in obese subjects, in Type 2 (non-insulin-dependent) diabetic patients and in angina pectoris. Attempts to decrease insulin resistance such as fasting, diet, or administration of an oral anti-diabetic drug such as Metformin induced a parallel decrease in plasma insulin and plasminogen activator inhibitor 1 levels. This inhibitor is produced by endothelial cells and by hepatocytes in culture. Plasminogen activator inhibitor 1 synthesis by hepatocytes in culture was stimulated by an increasing insulin concentration, or low density lipoproteins, whereas the endothelial cell synthesis was stimulated by very low density lipoproteins especially when they were obtained from hypertriglyceridaemic patients. Therefore, a direct effect of insulin or lipoprotein changes on the cells which synthesize plasminogen activator inhibitor 1 could be responsible for its increased plasma concentration in insulin resistance states. The increase in plasma plasminogen activator inhibitor 1 levels linked to hyperinsulinaemia is a tempting partial explanation for the association between insulin resistance and coronary disease.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Duguid JB (1946) Thrombosis as a factor in the pathogenesis of coronary atherosclerosis. J Pathol Bacteriol 58: 207–212
Schwartz CJ, Valente AJ, Kelley JL, Sprague EA, Edwards EH (1988) Thrombosis and the development of atherosclerosis: Rokitansky revisited. Semin Thromb Hemostas 14: 189–195
Bini A, Fenoglio JJ, Sobel J, Owen J, Fejgl M, Kaplan KK (1987) Immunochemical characterization of fibrinogen, fibrin I and fibrin II in human thrombi and atherosclerotic lesions. Blood 69: 1038–1045
Thompson WD, Smith EB (1989) Atherosclerosis and the coagulation system. J Pathol 159: 97–106
Wiman B, Hamsten A (1990) The fibrinolytic enzyme system and its role in the etiology of thrombo-embolic disease. Semin Thromb Haemostasis 26: 207–216
Paramo JA, Colucci M, Collen D, van der Werf F (1985) Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J 291: 575–576
Almer LO, Ohlin H (1987) Elevated levels of the rapid inhibition of plasminogen activator (t-PA) in acute myocardial infarction. Thromb Res 47: 335–339
Mehta J, Mehta P, Lawson D, Saldeen T (1987) Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 9: 263–268
Nilsson TK, Johnson O (1987) The extrinsic fibrinolytic system in survivors of myocardial infarction. Thromb Res 48: 621–630
Verheugt FWA, Ten Cate JA, Sturk A, Imandt L, Verhorst MJ, van Eenige MJ, Verwey W, Roos JP (1987) Tissue plasminogen activator activity and inhibition in acute myocardial infarction and angiographically normal coronary arteries. Am J Cardiol 59: 1075–1079
Aznar J, Estelles A, Tormo G, Sapena P, Tormo V, Blanch S, Espana F (1988) Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 59: 535–541
Francis RB, Kawanishi D, Baruch T, Mahrer P, Rahimtoola S, Feinstein DI (1988) Impaired fibrinolysis in coronary artery disease. Am Heart J 115: 776–780
Huber K, Rosc D, Resch I, Schuster E, Glogar DH, Kaindl F, Binder BR (1988) Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction. Thromb Haemostas 60: 372–376
Juhan-Vague I, Alessi MC, Joly P, Thirion W, Vague P, Declerck PJ, Serradimigni A, Collen D (1989) Plasma plasminogen activator inhibitor in angina pectoris. Influence of plasma insulin and acute-phase response. Arteriosclerosis 9: 362–367
Olofsson BO, Dahlen G, Nilsson TK (1989) Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 10: 77–82
Hamsten A, Wiman B, Defaire U, Blomback M (1985) Increased plasma level of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313: 1557–1563
Gram J, Jespersen J, Kluft C, Rijken DC (1987) On the usefulness of fibrinolysis variables in the characterization of a risk group for myocardial reinfarction. Acta Med Scand 221: 149–153
Hamsten A, Defaire U, Walldius G, Dahlen G, Szamosi A, Landov C, Blomback M, Wiman B (1987) Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet II: 3–9
Oseroff A, Krishnamurti C, Hassett A, Tang D, Alving B (1989) Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease. J Lab Clin Med 113: 88–93
Bavenholm P, Efendic S, Wiman B, Landou C, de Faire U, Hamsten A (1990) Relationship of insulin response to glucose challenge to severity and rate of progression of coronary atherosclerosis in young survivors of myocardial infarction. Eur Heart J 11: [Suppl 178] (Abstract)
Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1595–1607
Vague J (1956) The degree of masculine differentiation of obesities. A factor determining predisposition to diabetes, atherosclerosis, gout and uric calculous disease. Am J Clin Nutr 4: 20–28
Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Bjorntorp P, Tiblin G (1984) Abdominal adipose tissue distribution obesity and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br Med J 288: 1401–1404
Stout RW, Wallance-Owen J (1979) Insulin and atheroma. Lancet I: 1078–1080
Fontbonne A, Eschwege E (1987) Diabetes, hyperglycaemia, hyperinsulinaemia and atherosclerosis: epidemiological data. Diab Metab 13: 350–353
Pyőrala K (1979) Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease. Results from two population studies in Finland. Diab Care 2: 131–141
Welborn TA, Weame K (1979) Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diab Care 2: 154–160
Ducimetiere P, Eschwege E, Papoz L, Richard JL, Claude JR, Rosselin G (1980) Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 19: 205–210
Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D (1986) Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 35: 250–253
Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud MF, Atlan C (1987) Relationships between plasma insulin, triglyceride, body mass index and plasminogen activator inhibitor 1. Diab Metab 13: 331–336
Vague P, Juhan-Vague I, Chabert V, Alessi MC, Atlan C (1989) Fat distribution and plasminogen activator inhibitor activity in non diabetic obese women. Metabolism 38: 913–915
Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P (1989) Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients. Relationship with plasma insulin. Thromb Haemostas 61: 370–373
Shaw DA, McNaughton D (1963) Relationship between blood fibrinolytic activity and body fatness. Lancet I: 352–354
Ogston DM, Andrew GM (1964) Fibrinolysis in obesity. Lancet II: 1205–1207
Grace CS, Goldrick RB (1968) Fibrinolysis and body build. Interrelationships between blood fibrinolysis, body composition, and parameters of lipid and carbohydrate metabolism. J Atheroscler Res 8: 705–719
Almer LO, Janzon L (1975) Low vascular fibrinolytic activity in obesity. Thromb Res 6: 171–175
Epstein SE, Rosing DR, Brakman P, Redwood DR, Astrup T (1970) Impaired fibrinolytic response to exercise in patients with type IV hyperlipoproteinaemia. Lancet II: 631–634
Andersen P, Arnesen H, Hjermann I (1981) Hyperlipoproteinaemia and reduced fibrinolytic activity in healthy coronary high-risk men. Acta Med Scand 209: 199–202
Fearnley GR, Chakrabarti R, Avis PR (1963) Blood fibrinolytic activity in diabetes mellitus and its bearing on ischaemic heart disease and obesity. Br Med J 1: 921–923
Almer LO. Nilsson IM (1975) On fibrinolysis in diabetes mellitus. Acta Med Scand 198: 101–106
Auwerx J, Bouillon R, Collen D, Geboers J (1988) Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 8: 68–72
Legnani C, Maccaferri P, Tonini P, Cassio A, Cacciari E, Coccheri S (1988) Reduced fibrinolytic response in obese children: association with high baseline activity of the fast acting plasminogen activator inhibitor (PAI-1). Fibrinolysis 2: 211–214
Sundell IB, Nilsson TK, Hallmans G, Nygren C (1988) The effect on body build, diet and endocrine factors on the extrinsic fibrinolytic system in healthy young women. Scand J Clin Invest 48: 557–564
Grant MB, Fitzgerald C, Guay C, Lottenberg R (1989) Fibrinolytic capacity following stimulation with desmopressin acetate in patients with diabetes mellitus. Metabolism 38: 901–907
Sundell IB, Dahlgren S, Ranby M, Lundin E, Stenling R, Nilsson TK (1989) Reduction of elevated plasminogen activator inhibitor levels during modest weight loss. Fibrinolysis 3: 51–53
Sundell IB, Nilsson TK, Ranby M, Hallmans G, Hellsten G (1989) Fibrinolytic variables are related to age, sex, blood pressure, and body build measurements: a cross-sectional study in Norsjö, Sweden. J Clin Epidemiol 42: 719–723
Sundell IB, Nilsson TK, Hallmans G, Hellsten G, Dahlen GH (1989) Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a North Swedish population. Atherosclerosis 80: 9–16
Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, Smith U (1990) Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor 1. Metabolism 39: 1044–1048
Juhan-Vague I, Valadier J, Alessi MC, Aillaud MF, Ansaldi J, Philip-Joet C, Holvoet P, Serradimigni A, Collen D (1987) Deficient t-PA release and elevated PA Inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemostas 57: 67–72
Juhan-Vague I, Alessi MC, Fossat C, Valadier J, Aillaud MF, Serradimigni A (1988) Clinical relevance of high PAI-1 level in patients with idiopathic/recurrent deep venous thrombosis. Fibrinolysis 2 [Suppl 2]: 85–88
Landin K, Tengborn L, Smith U (1990) Elevated fibrinogen and plasminogen activator (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Int Med 227: 273–278
Almer LO (1988) Fibrinolytic disorders in diabetes mellitus. Diab Metab 14: 519–522
Gram J, Jespersen J, Kold A (1988) Effects of an oral antidiabetic drug on the fibrinolytic system of blood in insulintreated diabetic patients. Metabolism 37: 937–943
Ward WK, Lacava EC, Paquette TL, Beard JC, Wallum BJ, Porte D (1987) Disproportionate elevation of immunoreactive proinsulin in Type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 30: 698–702
Yoshioka N, Kuzuya T, Matsuda A, Taniguchi M, Iwamoto Y (1988) Serum proinsulin level at fasting and after oral glucose load in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 31: 355–360
Temple RC, Carrington CA, Luzio SD, Owens DR, Schneider AE, Sobey WJ, Hales CN (1989) Insulin deficiency in non insulin dependent diabetes. Lancet II: 293–295
Nagi DK, Hendra TJ, Ryle AJ, Cooper TM, Temple RC, Clark PMS, Schneider AE, Hales CN, Yudkin JS (1990) The relationships of concentration of insulin, intact proinsulin and 32–33 split proinsulin with cardiovascular risk factors in Type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 33: 532–537
Jackson RA, Hawa MI, Jaspan JB, Sim BM, Disilvo L, Featmerbe D, Kurtz AB (1987) Mechanism of Metformin action in non insulin dependent diabetes. Diabetes 36: 632–640
Chakrabarti R, Hocking ED, Fearnley GR (1965) Fibrinolytic effect of Metformin in coronary artery disease. Lancet II: 256–259
Vague P, Juhan-Vague I, Alessi MC, Badier C, Valadier J (1987) Metformin decreases the high plasminogen activator inhibitor capacity, plasma insulin and triglyceride levels in non diabetic obese subjects. Thromb Haemostas 57: 326–328
Golay A, Felber JP, Dusmet M, Gomez F, Curchod B, Jequier E (1985) Effect of weight loss on glucose disposal in obese and obese diabetic patients. Int J Obes 9: 181–190
Mehrabian M, Peter JB, Barnard RJ, Lusis AJ (1990) Dietary regulation of fibrinolytic factors. Atherosclerosis 84: 25–32
Huisveld IA, Leenen R, vdKooy K, Hospers JEH, Seidell JC, Deurenberg P, Koppeschaar HPF, Mosterd WL, Boupma BN (1990) Body composition and weight reduction in relation to antigen and activity of plasminogen activator inhibitor (PAI-1) in overweight individuals. Fibrinolysis 4: 84–85
Simpson HCR, Mann JI, Meade TW, Chakrabarti R, Stirling Y, Woolf L (1983) Hypertriglyceridaemia and hypercoagulability. Lancet I: 786–789
Rosenthal M, Haskell WL, Solomon R, Widstrom A, Reaven G (1983) Demonstration of a relationship between the level of physical training and insulin stimulated glucose utilization in normal humans. Diabetes 32: 408–411
Speiser W, Langer W, Pschaick A, Selmayr E, Ibe B, Nowacki PR, Muller-Bergaus G (1988) Increased blood fibrinolytic activity after physical exercise: comparative study in individuals with different sporting activities and in patients after myocardial infarction taking part in a rehabilitation sports program. Thromb Res 51: 543–555
Estelles A, Aznar J, Tormo G, Sapena P, Tormo V, Espana F (1989) Influence of a rehabilitation sports program on the fibrinolytic activity of patients after myocardial infarction. Thromb Res 55: 203–212
Gris JC, Schved JF, Aguilar-Martinez P, Arnaud A, Sanchez N (1990) Impact of physical training on plasminogen activator inhibitor activity in sedentary men. Fibrinolysis 4: 97–98
Loskutoff DJ, van Mourik JA, Erickson LA, Lawrence D (1983) Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci USA 80: 2956–2960
Sprengers ED, Princen HMG, Kooistra T, van Hinsberg VWM (1985) Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line HepG2. J Lab Clin Med 105: 751–758
Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D (1988) Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line HepG2. Thromb Haemostas 60: 491–494
Kooistra T, Bosma P, Tons H, van den Berg A, Meyer P, Princen H (1989) Plasminogen activator inhibitor 1: biosynthesis and mRNA levels are increased by insulin in cultured human hepatocytes. Thromb Haemostas 62: 723–728
Anfosso F, Alessi MC, Latron Y, Juhan-Vague I (1990) IGF-1 increases PAI-1 synthesis by human hepatoma cell line HEPG2. Fibrinolysis 4 [Suppl. 3]: 175 (Abstract)
Grant PJ, Kruithof EKO, Felley CP, Felber JP, Bachmann F (1990) Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor 1 concentrations in man. Clin Sci 79: 513–516
Potter van Loon BJ, de Bart ACW, Radder JK, Frolich M, Kluft C, Meinders AE (1990) Acute exogenous hyperinsulinaemia does not result in elevation of plasma plasminogen activator inhibitor 1 (PAI-1) in humans. Fibrinolysis 4: 93–94
Juhan-Vague I, Vague P (1991) Hypofibrinolysis and insulin resistance. Diab Metab 17 [Suppl. 2]: 96–100
Kluft C, Jie AFH, Rijken DC, Verheijen JH (1988) Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast acting inhibitor PAI-1. Thromb Haemostas 59: 329–332
Medvescek M, Keber D, Stegnar M, Borovnicar A (1990) Plasminogen activator inhibitor 1 response to a carbohydrate meal in obese subjects. Fibrinolysis 4: 89–90
Williams JF, Olefsky JM (1990) Defective insulin receptor function in down-regulated HepG2 cells. Endocrinology 127: 1706–1717
Melin B, Cherqui G, Blivet MJ, Caron M, Lascols O, Capeau J, Picard J (1990) Dual effect of Metformin in cultured rat hepatocytes: Potentiation of insulin action and prevention of insulin-induced resistance. Metabolism 39: 1089–1095
Olefsky JM, Farquhar JW, Reaven GM (1974) Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med 57: 551–560
Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J (1990) Secretion of plasminogen activator inhibitor 1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 10: 1067–1073
Latron Y, Alessi MC, Anfosso F, Nalbonne G, Lafont H, Juhan-Vague I (1990) Effect of low density lipoproteins on secretion of plasminogen activator inhibitor 1 (PAI-1) by human endothelial cells and hepatoma cells. Fibrinolysis 4 [Suppl 2]: 82–83
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Juhan-Vague, I., Alessi, M.C. & Vague, P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 34, 457–462 (1991). https://doi.org/10.1007/BF00403280
Issue Date:
DOI: https://doi.org/10.1007/BF00403280